Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06459180
Status:
RECRUITING
Last Update Posted:
2024-06-14
First Post:
2024-06-10
Brief Title:
A Study to Compare Sacituzumab Tirumotecan MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer MK-2870-020TroFuse-020Gog-3101ENGOT-cx20
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Organization Data
Organization:
Merck Sharp Dohme LLC
Class:
INDUSTRY
Study ID:
2870-020
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck Sharp Dohme LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| GOG Foundation | NETWORK |
| European Network of Gynaecological Oncological Trial Groups ENGOT | OTHER |